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INTRODUCTION 
Owing to their unique abilities of rapid computation, and 
man's abilty to reduce complex problems and thoughts to exercises 
in binary arithmatic, digital computers have revolutionized many 
fields in the natural and social sciences. One such area is the 
study of pharmacokinetics. A brief history of the field will 
exp lain. 
It is believed (65) that the originator of mu It i comp ar tmen t 
analysis of "tracer" or (as it has now come to be referred to) 
pharmacokinetic data was Teorell (78) who in 19 37 proposed that 
physiologically the body behaved as a two-co mp ar tmen ta 1 open 
system, rather than as a single compartment. Riggs, in 1963, 
(66) was one of the first to give a rigorous mathematical 
treatment to many of the theories and observations that had been 
set forth concerning the existence of biophysiologic compartments 
and the kinetics of substance transfer between them 
(11 ,19 , 20,5 5 ,7 1 ,7 2 ,7 5 ,76 ,78) . 
As he stated, a common mathematical form for the general 
equation of compar tmen ta 1 analysis is: (see Appendix A for 
detailed derivation) 
cp = r Cj*e-Vt 
i =1 
(#1) 
where Cp = drug concentration in plasma 
C i = Cl, C2 Cn = numerical coefficients 
>i = 1, 2 n = numerical exponents 
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e = the natural base e 
t = time 
= multiplication symbol 
Most often, this analysis is used to understand the behavior 
of a substance following bolus intravenous injection at time t=0 
with subsequent frequent determinations of plasma concentration. 
(This route of administration is the most common as it allows one 
to assume that drug absorption is essentially instantaneous and 
complete, thus greatly simplifying calculations). If the body is 
treated as exhibiting the behavior of a single compartment a 
schematic view would be as shown in figure 1. The corresponding 
equation, derived from equation #1 would be: 
Cp = C*e-^*t (#2) 
However, as Riegelman et al. (65) and others have discussed, it 
is physiologically and mathematically more accurate to use a 
two—compartment open model with elimination from the central 
compartment. Such a model is shown in figure 2 and is 
represented by the equation: 
CP = C1*e-^l*t + C2*e-^2*t (#3) 
This is frequently rewritten as 
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FIGURE 1 
I I Kel 
> | BODY | -> 
Kel constant of elimination of drug from the single compartment 

J TWO-COMPARTMENT PHARMACOKINETICS P age 4 
FIGURE 2 
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Kel = constant of elimination 
compartment. 
of the drug from the central 
kl2 = constant of transfer of 
peripheral compartment. 
the d rug from the central to the 
k21 = constant of transfer of 
central compartment 
the drug f rom the peripheral to the 
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for ease in referral to the various constants. (Whenever 
possible this notation will be used for the remainder of this 
paper) . 
Just as we derived figure 2 from the format of figure 1 by 
the insertion of another compartment, in an analogous fashion an 
infinite number of additional compartments with access to and 
from the central compartment described by constants kl3/k31, 
kl4/k41 etc. can be added. In practice, it is rarely necessary 
to refer to any model more complex than three compartments (11 - 
ref. 10) as even a large number of physiological constants can be 
combined, and an essentially equivalent, yet simpler, model 
derived. 
Note here, that each compartment has a unique set of 
entrance and exit constants (referred to here as klN and kNl 
respectively). Each constant describes the rate of drug movement 
in one direction only, and contrary to our intuitive sense, is 
not necessarily equal to its partner. Indeed movement in the 
opposite direction may occur at a wholly different rate, 
presumably due to variations in transport mechanism, membrane 
permeability, protein binding etc. 
In this system of modeling, compartment one, often referred 
to as the central compartment, represents that area of the body 
into which the drug is introduced, in the sense that it will be a 
medium of drug transport throughout the body. All excretion of 
the drug from other compartments must be mediated via the central 
compartment. This is usually felt to typify the plasma 
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(27,38,65,66) but could conceivably include extracellular fluid 
or some portion thereof, if this portion was always in a constant 
equilibrium with the plasma, with respect to the drug in question 
(i.e., if klN and kNl equaled infinity). 
The second compartment, often called the tissue compartment, 
"is not clearly identified but presumably includes at least some 
'intracellular fluid' " (66, p. 205). Its distinguishing 
characteristic is the existence of a finite kinetic constant k, 
which can be utilized to derive the rate at which a drug enters 
(or leaves) the tissue compartment from (or into) the central 
one. The relevant equation is: 
dC/dT = kC (#5) 
This indicates that the instantaneous rate of change in 
concentration of a drug in a given compartment at a given time, 
is the product of the constant k, and the concentration C at that 
point in time. 
If a third compartment is invoked it might be referred to as 
a "slowly accessible" tissue space, whereas the second one would 
be "rapidly accessible" (38). In the model we are considering, 
access to and from the third compartment is via the central one 
only. Finally, in this type of model it should be re-emphasized 
that all elimination from the body occurs via the central 
compartment. Thus a drug in the tissue compartment (e.g.. 
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adipose tissue) must first return to the central compartment 
before it is excreted by the appropriate means (whether in the 
urine, feces, sweat, etc.) 
THEORY 
The reason that a given drug is subjected to pharmacokinetic 
evaluation is that once the appropriate constants are derived, 
one can calculate the half-life, volume of distribution and other 
relevant values which can then be used to plan rational drug 
therapy with respect to dose, dosage interval, desired peak and 
trough blood levels (82, also see Appendix A). The last item can 
be particularly important when using agents where one needs to 
attain a certain peak level for efficacy yet also achieve a given 
trough to minimize toxicity. Clinically this becomes difficult 
when drugs have a low therapeutic index. The most frequent such 
situations encountered are probably with the aminoglycosides, and 
cardiac glycosides. 
With a single-compartment model, there are only two 
parameters of interest k, and Vd (the volume of distribution of 
the drug). These may be considered to be roughly equivalent to, 
or derivable from, the terms in equation #2. Calculation of C is 
relatively simple. Equation #2 may be converted to equation #6 
(below) by taking the natural logarithm of both sides: 
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![ 
log Cp = + C (#6) 
This equation is linear, and of the form Y = mX + B. When a 
plot of log Cp vs t is made, the slope is and the y-intercept 
is C. Then, using simple linear regression (21, p. 1-43) an 
exact solution for all constants can be found. 
Unfortunately, with higher order models, the situation is 
not as straight-forward. For illustrative purposes, consider the 
two-compartment model. Here, there are four constants (see 
Figure 1) kl2, k21, klO and Vp. These can be converted to the 
, four constants of equation #4 — A, A1pha ,B and Beta — 
using methods outlined in Appendix A. While this second set of 
constants is "equivalent" in the sense that each set is derivable 
from the other (as with the single-compartment model), there is 
no direct correlation between any members of each set, but rather 
a complex inter-relationship (64,80,82 p. 254-257). 
Problems arise when one takes the logarithm of equation #4: 
log Cp = log (A*e~oi*t + e*e“^*t) (#7) 
Equation #7 cannot be simplified further due to the limitations 
of logarithmic manipulations (see Appendix B). Thus it cannot be 
"linearized" as was done with equation #2 and no exact solution 
exists, only estimated ones (21, p. 263-304) 
In the early days of pharmacokinetics most investigators 
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used one-compartment models in treating their data (even if they 
did not think of it this way at the time, compartmenta1 theory 
being quite new). Thus, the problem of how best to estimate 
two-compartment parameters, was not a problem, or at least not a 
recognized one. However in the late 1940's and early 1950's, 
when scientists began to analyze their data in this fashion 
(19,55,66,75,76), a search began for good non-linear methods of 
estimation. Eefore the availability of digital computers or 
calculators, the commonest way to estimate the parameters was to 
try to manually/visually resolve the plot of log Cp vs time into 
its two component curves (9). Each curve could then be treated 
as a separate problem in one compartment kinetics and all 
parameters be obtained. This method is one of curve "stripping" 
or "peeling". 
However curve stripping is a process based on an incorrect 
assumption. While it is true that the first term of the right 
_C\* ^ 
side - A*e - constitutes most of (and contributes primarily 
to) the initial so-called "alpha" phase of the curve (see Figure 
I -fb* t 
3), with the term B*e being similarly associated with the 
"beta" phase, this is indeed just an association, and each term 
clearly contributes to values thoughout the entire curve 
(56,57,60) . In fact, the closer the values of Alpha and Beta 
- - 
are to each other, the more difficult they will be to separate 
(either manually or by computer) (46). In addition, experimental 
error, or lack of data points at crucial times (i.e., around the 
I 










Typical plot of log Cp vs 
intravenous injection and 
pharmacokinetic behavior, 
"alpha" phase (left) from 
time for a drug introduced by bolus 
exhibiting two-compartment 
The arrowhead separates the so-called 
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curve "crossover") can present great problems (60). 
The reason crude methods such as visual resolution were 
employed was that more accurate solutions required non-linear 
regression analysis using complex iterative techniques involving 
innumerable detailed calculations (21) (see appendix B for 
reasons why iterative techniques must be used, and an appropriate 
example of these methods). With the advent of digital computers 
it suddenly became feasible to apply these iterative methods and 
obtain much improved solutions. Predictably, over the next few 
years many programs appeared in the literature and were 
I 
applied to both new and existing pharmacokinetic data 
(3,6 ,9 ,1 3,24,25,35,36,4 0- 42 ,4 4 ,45 ,52,57 ,59 ,6 0 ,62,6 9 ,88-9 0). 
Some of these are capable of examining data for a two, three 
or more compartment fit and, using various criteria, of selecting 
the best fit (36,42,57,62,89). Others limit themselves to 
two-compartment evaluation (44,59,60,90). 
As is a feature of iterative techniques in general, some 
starting value for each parameter in question is needed as an 
initial crude estimation which will then be refined by the 
program. As many workers in the field have noted, the speed with 
which the interation converges upon a solution, and even whether 
or not it will converge at all, is very dependent on the choice 
of good starting values, i.e., initial estimates 
(21,44,56,57,60,77); see also Appendix B for details. 
Most of the programs mentioned obtain their starting values 
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via computerized curve peeling/stripping, i.e., a subroutine of 
the program which "separates" the curve into its "alpha" and 
"beta" phases (assuming a two-compartment model; with a three- 
compartment model the final phase might be the "gamma" phase). 
This, as mentioned above, is precisely what was done manually 
before computers became available. Once curve stripping has been 
done it is simple to apply one-compartment models to each phase, 
calculate the appropriate parameters, and use these as the 
initial estimates for non-linear regression analysis. 
Many of these programs require a large computer system. 
Recognizing that not everyone has access one, several 
self-contained curve-stripping programs have been published 
(12,26,36,50,68), to be run on mini-computers or programmable 
calculators. These are intended to be run separately to provide 
good initial parameter values which can subsequently be used as 
starting points for non-linear regression, or can even themselves 
suffice as "final" values if only rough estimates are needed. 
Perhaps the most impressive achievement in this area is that of 
Muir (44) who devised a non-linear least squares regression 
analysis program for use on a TI-59 pocket programmable 
calculator. 
When published reports of comparisons of the various 
programs (using the same sets of data) are examined, it is 
evident that in the vast majority of cases, the values obtained 
are within 25% of each other. For example, Muir's TI-59 program 
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(44) yields almost identical results as the program NONLIN (57) 
in the two-compartment data analysis used. Similarly Yeh and 
Kwan (90) compare results with the program COMPT (60) and three 
out of four parameters are within 25% of each other. Wijnan and 
I 
Timmer (86) compared four different programs. In 15 out of 16 
parameters calculated results varied by less than 20%. Various 
calculated values for the remaining parameter vary by over 100%, 
although it should be noted that this parameter was one to two 
orders of magnitude less than the others, and thus larger 
differences between programs were of less ultimate significance. 
The lesson here is that while there may be inter-program 
differences in parameter estimation that is of great interest to 
the pharmacokineticist and/or computer programmer, these 
differences are rarely of such a magnitude as to be of practical 
interest to the clinician. Indeed one can show (see Appendix C) 
that over a given time period after drug administration (i.e., 
the period before the next scheduled dose), quite similar 
predicted drug levels may be calculated using remarkably 
different sets of parameters. Additionally when calculations are 
carried one step further parameters differing by as much as 30% 
do not yield significantly different drug doses or dosing 
schedules for most medications (see again Appendix C). It would 
appear that the "balance" of an entire set is more important than 
differences seen between individual items in given sets. 
All of the programs mentioned above require some form of 
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advanced knowledge in order to be used. This ranges from a 
relatively minor pre-requisite of knowing how the data is to be 
entered and what other information is required, to writing a 
short FORTRAN IV computer program that "runs" the original 
program (42). In addition, the output of these programs are 
often in complex form and without any documentation, thus 
rendering them practically un interpretable. For example, none of 
the programs have sub-routines included which will provide 
explanation or directions at run time (the actual time of program 
execution), or which will aid the user in processing the final 
parameters once they have been calculated. Even with the 
appropriate documentation found in the literature describing the 
programs it is obvious that they are not designed for use by the 
inexperienced. 
Given this state of affairs, it would appear that many 
existing computer programs, while of great utility to 
pharmacologists studying the kinetics of a drug, are of limited 
use to clinicians. 
With this in mind I wrote the computer program NOVICE, which 
is described below. It allows for most of the features of the 
previously mentioned programs. Specifically, it will treat data 
from IV bolus drug injection or peroral administration in a 
two-compartment fashion by performing curve-peeling to arrive at 
initial parameter estimates. NOVICE then will utilize a modified 
version of COMPT (60) (a non-linear regression program) to 
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perform non-linear least squares analysis using these initial 
estimates. 
NOVICE has extensive documentation and instructions for the 
user and is designed to be accessible to the clinician with only 
a very limited pharmacokinetic or computer backround. It 
provides for substantial run-time interaction, allowing the user 
flexibility in deciding how to treat the data. Much of this 
flexibility has been extended to COMPT. NOVICE is also equipped 
with a library of appropriate parameters for commonly used drugs, 
these having been derived from population studies. (These drugs 
include: penicillin G, ampicillin, methicillin, oxacillin, 
erythromycin, cephalexin, cephradine, cefazolin, cephalothin, 
I 
cefoxitin, theophylline, digoxin, propranolol, lidocaine, 
procainamide, quinidine, bretylium.) The user has access to 
these either for comparison with his/her own data, or for 
simulation of drug kinetics under varying conditions. 
NOVICE was designed to be used in conjunction with an 
existing program, LEVEL3 (77) which will take the calculated 
parameters and, again with extensive run-time interaction, allow 
the user to design a schedule for drug administration. The user 
is able to choose desired serum levels, dose, dosing interval 
etc., and thus will be able to rapidly and directly apply the 
parameter values from NOVICE to the clinical setting. 
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NOVICE is a 2700 line program written in the language 
AlphaBASIC (2), a superset of BASIC marketed by Alpha 
Microsystems, Irvine, CA. It was written on an Alpha 
Microsystems model AM-1051 computer (using facilities kindly 
■ provided by Clinical Analytics, Inc., New Haven, CT) but may be 
used with all Alpha Microsystems and Olivetti S-6000 computers. 
A complete listing of the program is available from the author 
upon request. A flow chart is presented in Figures #4-8. A 
detailed description of the program is presented below. 
NOVICE itself performs curve stripping. The values derived 
serve as initial estimates for non-linear regression analysis as 
performed by a modified version of the program COMPT (60). 
Source code for this program can be found in the original 
reference. 
Testing of the program consisted of using data sets which 
had served as input for several other non-linear regression 
programs, results of which appeared in the literature 
(6,36,42,44,73,81,90). This data was used as input for NOVICE 
and the parameters obatined were compared with the previously 
published results. 
NOVICE PROGRAM SEQUENCE 
The user is first given the opportunity to view a detailed 
set of directions. He/she must then to choose between either 
utilizing existing pharmacokinetic data (herein referred to as 

TWO-COMPARTMENT PHARMACOKINETICS Page 17 
utilizing existing pharmacokinetic data (herein referred to as 
the "HAVE1DATA" mode) or running a simulated trial (the 
"EQUATION" mode). 
The trial assumes IV bolus drug administration, and lets 
one introduce a fixed amount of random error (scatter) into 
a theoretical data set, generated by having the user type 
in known values of A, B, Alpha and Beta, or, if preferred, 
for kl2, k21, kel and Vp. Known values for commonly 
used drugs are provided if desired. These values have 
been gathered from population studies in the literature 
(1,8,10,18,22,23,29,33,37,39,48,49,51,53,61,67,85). The scatter 
takes the form of a maximum error from the ideal that can be 
tolerated (e.g., 10%), which is then used to derive a standard 
deviation for the error distribution (which is normal with a mean 
of 0%). The standard deviation, at any sample point, is the 
product of the drug levels and the maximum deviation. This is 
similar to the procedure outlined by Cutler (15). The number of 
simulated drug levels is preset at 10. These are spaced 
logarithmically and are designed so as to cover a period of 2-3 
half-lives of the drug in question. The original purpose of this 
simulation was to provide data sets to use in testing the curve 
peeling sub-routine of NOVICE. The introduction of random error 
to the data sets is necessary since a curve peeling algorithm may 
work perfectly with perfect data but give markedly inaccurate 
results when an element of scatter is introduced into one of the 
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variables. Since such error will always be present to a greater 
or lesser degree in any measurements make in a clinical setting, 
it is appropriate to introduce it in data simulation. It soon 
became obvious that simulation might be useful in others ways as 
well (see below) and it was integrated into the final version of 
the program. 
In the HAVE'DATA mode the user analyzes a set of serum drug 
levels which have already been obtained. The data may be entered 
at run time, or optionally stored in a data file which is then 
specified by name at the program's execution. If data is 
supplied by the user, he/she will be asked for the drug name. If 
it is a commonly used drug, known parameter values from the 
literature will be made available later for comparison. With 
user-supplied data, the drug dosage is also required. 
Additionally, with existing data, the program requests the 
route of administration. If the route is intravenous, then all 
the data entered is used in the program. If instead peroral 
administration is used, the program searchs for peak serum drug 
levels, and discards all levels prior to the peak. It then 
treats the data as if they referred to an IV bolus injection with 
the first level being the peak level and having a time=0 assigned 
to it. (The implications of this are discussed below). 
In either mode, the user then has the opportunity to select 
what units of drug dosage and serum drug levels should used in 
data input and output. 
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be used in determining the best fit. The weighting factor, 
abbreviated as W is used in the equation describing the weighted 
sum of the squared residuals (SS) below: 
SS = j? (C ' • - C . ) 2/ W ; , 1 l' (#8) 
i =1 
where C = measured serum drug level 
C'= serum drug level calculated by regression (or curve 
peeling) derived pharmacokinetic parameters. 
The user is given a choice of four weighting factors. The 
details and rationale of this system are discussed below. 
After the weighting factor has been entered the program 
requests information for use in its non-linear regression phase. 
This consists of the convergence testing factor (CTF) and the 
maximum number of iterations to be used. The CTF is the value 
used to test whether the iterative technique has led to 
convergence for a minimum value for SS. The actual equation is 
(60) : 
(SS . ,, - SS.)/ SS. <= CTF 
l + l l l 
(#9) 
CTF is set by default to 1 * 10 
-6 
(IE-6 in computerized 
notation), and the maximum number of iterations is set to 100. 
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notation), and the maximum number of iterations is set to 100. 
The user may change both of these if desired. If at any point in 
the iterative process the criterion of equation #9 is satisfied a 
"tentative" solution will be deemed to have been reached. (See 
Appendix D for details on how the "final" solution is actually 
reached). If the CTF is achieved, the number of iterations 
actually performed will be sub-maximal. If however, the solution 
converges so slowly that the CTF is never attained, after the 
maximum number of iterations, the program will cease cycling and 
use the last solution as its "tentative" one. 
At this juncture, all the data and necessary criteria have 
been entered. It should be noted that all questions posed to the 
user, for which the programmer can suggest a probable response 
(e.g., the value for CTF) are handled by a special routine which 
asks the question and follows it with the expected response. The 
program then pauses and allows the user to either approve of this 
answer (by typing an carriage return) or to enter his/her own 
reply in its place. 
The program now proceeds in its calculations. A flow chart 
is provided in Appendix E. Essentially, the program performs 
sequential curve stripping starting with the assumption that the 
"beta" phase is represented wholly by the last two data points 
and ending with the assumption that is it represented by all but 
the first two data points. All points not in the "beta" phase 
are automatically assigned to the "alpha" phase. If there are N 
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data points, this will yield N-3 possible combinations as 
theoretical models. 
For each model a weighted SS is computed. This is done by 
calculating values for A, Alpha, B and Beta for each model 
via linear least squares. Then, using these values, the curve is 
reconstructed yielding "calculated" drug levels at the 
appropriate times. The calculated levels (C') are compared with 
the actual levels (C) and using the weighting factor selected by 
the user, SS's are determined. The model with the lowest SS is 
chosen within the limits of certain constraints. These are: 
1. If the program is using data generated by random scatter 
about input parameters (i.e., the EQUATION mode) then no 
model is acceptable if any of its parameters vary by 
more than a factor of two from their corresponding input 
(or idealized) parameter. 
2. Whether the EQUATION or HAVE'DATA mode is being used, 
all chosen parameters must be greater than zero. 
If no model satisfies the criteria above an appropriate message 
is printed. In the HAVE'DATA mode this indicates that the 
probable reasons for failure to find a model were that either 
data entry was done incorrectly (e.g., not in chronological 
order) or that the model could not be fit to two-compartment 
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pharmacokinetics. In the EQUATION mode, it is explained that in 
all likelihood the error chosen was too large. The user is then 
allowed to reset the error and/or parameters as desired. 
Once the model is chosen, the program outputs values for the 
number of points considered to constitute the "beta" phase and 
the parameters of that phase, B and Beta. It then displays the 
values calculated with the remaining points for A and Alpha. 
Standard errors for each phase are also given. 
The user then has the option of viewing the following data 
for each model, or for just the model chosen: calculated values 
for A, Alpha, B and Beta, input values for A, Alpha, B and 
Beta (if applicable), a table comparing values for actual drug 
levels and calculated ones at each time, the weighted SS, and the 
correlation coefficient. If the program is being run in the 
EQUATION mode, the table will include a drug level assuming no 
error, and three weighted SS1s will be given, comparing all 
combinations of "perfect" data (with no error), "given" data 
(with error), and "generated" or "calculated" data (levels 
calculated by the program using the best model, which was chosen 
to minimize the SS of given vs generated data). Following this, 
the parameters A, Alpha, B and Beta may be converted to kl2, 
k21, kel, and Vp if desired. 
Next, the program allows the user to compare the calculated 
parameter values with those derived from population studies, if 
the drug being used is one for which this data has been put in 
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the program's drug library. 
The user may now reset the weighting factor. If he/she 
desires to do so, the program will then recycle through all 
pertinent routines using this new weight and will display the 
model chosen accordingly. New weighting factors may be selected 
until all have been chosen. 
After each model calculation using a new weighting factor, 
the user may view a table of values for each parameter as 
calculated with the different weights used up to that point. 
This is intended to aid the user in the next task, which is 
selecting which of the weighting factors should be the one used 
in the remainder of the program. Once this weight is chosen, (if 
the HAVE'DATA mode is being utilized, and least squares analysis 
was requested) the program runs non-linear regression using an 
adapted version of the program COMPT (60). 
Some of these changes were necessary as COMPT is written in 
one superset of BASIC (Leasco Time-Sharing modification of the 
Hewlett-Packard interpreter) (60), while the AlphaMicro AM-1051 
uses a different superset, namely AlphaBASIC. Most changes in 
source code involved problems of syntax. (Source code is the 
text form of the program is written by the programmer in a "high 
level language," analagous to English. Source code must be 
translated by the computer into object code, the sequence of 
numbers, expressed as 0's and l's, which directs the steps the 
computer must take to execute the program.) However, AlphaBASIC 
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does not have a system command capability for matrix manipulation 
which was present in the original language of COMPT. Thus, 
appropriate subroutines for matrix addition, matrix 
multiplication, matrix inversion and scalar multiplication were 
added using programs from Poole and Borchers (63) as a model. In 
addition, new routines for matrix equalization and matrix 
transposition were written by the author. Other changes made in 
COMPT included provisions for varying weighting factors and 
alterations in the format of data input and output. The 
mathematical and statistical portions of the program were left 
essentially intact. 
After non-linear regression analysis has been finished, 
control of the program returns back to NOVICE, all major 
calculations having been completed at this point. The user now 
views the final data using the same format as had been applied 
previously (i.e., for the preliminary model derived from curve 
stripping); to this is added the number of iterations, 
convergence, standard deviations of the parameters, and 
appropriate half-lives. Program execution is now transferred to 
LEVEL3, which has been briefly described above. A demonstration 
of this can be found in Appendix F. If non-linear regression 
analysis was not done, transfer to LEVEL3 occurs whenever the 
user declines to reset the weight. 
In addition, I have created a program entitled SINGLE, which 
is a version of NOVICE edited to perform one-compartment 
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pharmacokinetic calulations. I applied it to data sets subject 
to analysis by NOVICE to demonstrate the difference in parameters 
obtained when one assumes a one- vs two-compartment model. 
RESULTS 
Sample program executions which demonstate style and format can 
be found in Appendix F. 
Table I below compares NOVICE with a curve-peeling program 
written by Foss (26), using tracer data cited and reproduced by 
that author. Here, NOVICE was able to duplicate the original 
results, when the proper weighting factor (so as to maximize the 
correlation coefficient) was used (i.e., unweighted). (A more 
detailed discussion of weights and correlation coefficients will 
be presented below). 
Table II compares NOVICE and NOVICE/COMPT with results of 
Smith et a 1. (73) using their original data for pentobarbital 
(IV injection) and a non-linear regression program SAAM-23 (6). 
In none of these cases is there an exact duplication of results, 
however this would not really be expected. Although 
curve-peeling is a standardized procedure, non-linear regression 
is not (as evidenced by the large number of programs written to 
perform it). The scheme used in COMPT is but one of many 
feasible for the process. What is evident, is that in almost 
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TABLE I 
A Alpha B Be ta SS CC 
Foss 9.294 0.8596 1.134 0.3113 
wt (5) 
NOVICE 9 . 292 0.859 1.134 0.3113 0.01748 0.9998 
wt (1 ) 
NOVICE 
WT (2) 
9.8 58 0.7468 0.1895 0.1646 0.04785 0.9985 
NOVICE 10.79 0.784 0.1222 0.1330 0.4584 0.9969 
wt ( 3 ) 
NOVICE 10.79 0.7846 0.1222 0.1330 0.1148 0.9969 
wt (4 ) 
SINGLE 4.003 0.4275 0.5915 
Weight codes are as follows: 
1 = 1 
2 = 1/C 
3 = 1/C2 
4 = 1/(C + C' ) 2 
5 = 1/2 
where C = the actual drug level 
C' = the calculated drug level 
<S = the variance (available only for multiple samples) 
CC = the correlation coefficient 
Units of A and B are mg/hr. Units of Alpha and Beta are 1/hr. 
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TABLE II 
















0.0067 0.995 2.4 1.7 
wt(3 & 4) 












0.0334 0.951 2.7 2.1 
wt(3 & 4) 












0.0418 0.979 0.3 9.7 
wt(3 & 4) 












0.1293 0.975 7.9 1.1 
wt (3) 
NOVICE/ 1.408 0.646 0.030 45.2 0.125 7.9 0.5 
COMPT 
NOVICE 1.943 0.7 26 0.038 38.3 0.0295 0.977 13.9 14.9 
wt (4 ) 
NOVICE/ 1.701 0.650 0.033 40.4 0.0273 3.0 10.2 
COMPT 
(Continued on next page) 
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% kel % Vp 
k 12 k 21 kel Vp SS CC diff diff 
Subject V 
Smith 0.455 0.281 0.0 36 46 0.11 
NOVICE 
wt (3 & 
0.367 
4) 
0.233 0.033 54.6 0.123 0.949 7.2 18.7 
NOVICE/ 
COMPT 
0.529 0.312 0.039 49.7 0.123 9.4 8.0 
Weight codes are the same as in Table I 
CC = Correlation Coefficient 
Use of NOVICE/COMPT is always with the weight(s) listed 
immediately above for NOVICE alone. In the case of multiple 
weights, weight #4 was used to calculate the SS. 
Units of kl2, k21, and kel are 1/hr. Units of Vp are liters. 
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all cases COMPT improved NOVICE'S initial results (with respect 
to duplicating Smith's SAAM-23 answers - whether or not this 
actually is an improvement is debatable). In only one instance 
(case IV) did the two primary data weighting schemes give 
different results. For comparison's sake, the percent difference 
,| 
between kel and Vp were used - kel since it is used to calculate 
the plasma half-life, possibly the most important parameter to 
clinicians, and Vp because it is a "global" parameter derived 
from all the others. Table III compares NOVICE with results from 
Muir's TI-59 program (44), and NONLIN (42), on data cited and 
reproduced by Muir. COMPT was not utilized on this data as drug 
dosage was not supplied, and interconversion from A, Alpha, B 
and Beta (the parameters used by Muir and NOVICE) to kl2, k21, 
kel and Vp (the parameters used by COMPT) requires this piece of 
information. Two points bear mention. First, while it is 
obvious that parameters calculated by NOVICE differ by as much as 
a factor of about 70 from those of NONLIN, in no case does the 
best NOVICE model (as measured by the correlation coefficient) 
produce drug levels which on the average differ from the actual 
drug levels by more than 20%. (Indeed, in but one case the 
average difference is less than 10%). Thus, as was mentioned 
above, markedly different parameters can, as a group, yield quite 
similar (and accurate) blood levels. Secondly, the original 
table by Muir (44) , not reproduced here, gives standard 
deviations for the parameters, which in some cases are as much as 
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TABLE III 
Co r r Avg Level 
A A1 pha B Be ta Coef f Di ff 
Subject I 
MONLIN 0.94627 0.03761 0.2374 8 0.00209 
n-59 0.94638 0.03760 0.23729 0.00209 
MOVICE 0.74885 1.9388 0.25221 0.14185 0.960 8.4 
wt (3) 
MOVICE 0.84925 2.24801 0.30220 0.17189 0.987 5.9 
wt (4) 
Subject II 
NONLIN 10.5271 0.39822 0.61991 0.00685 
TI-59 
NOVICE 
10.5236 0.39817 0.61984 0.00685 
0.57710 2.19310 0.40135 0.24004 0.879 20.9 
wt (3) 
NOVICE 0.86887 4.3534 0.44044 0.25993 0.925 20.0 
wt (4 ) 
Subject III 
NONLIN 0.60006 0.02441 0.0 9298 - 0.00012 
TI-59 0.60065 0.02440 0.09265 - 0.00015 
NOVICE 0.64224 2.52802 0.17082 0.10646 0.965 8.2 
wt (3 & 4) 
Subject IV 
NONLIN 1.23932 0.09393 0.64843 0.00560 
TI-59 1.23997 0.09422 0.64955 0.00561 
NOVICE 1.16726 4.64235 0.58951 0.2 9353 0.990 4.8 
wt (3 & 4) 
Subject V 
NONLIN 1.71104 0.10826 0.44583 0.00254 
TI-59 1.71174 0.10852 0.44663 0.00259 
NOVICE 1.23140 3.54244 0.33794 0.07995 0.9 36 9.5 
wt (3) 
NOVICE 1.37386 4.2 0068 0.35905 0.09291 0.950 8.8 
WT( 4 ) 
Units of A and B are mg/hr Units of Alpha and Beta are 1/hr 
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ten times greater than the parameter values themselves. Thus, 
even with NONLIN, which is "probably the most frequently used 
[program]" (44), confidence limits can be huge. In one case, the 
programs even arrived at a negative value for Beta. 
Table IV compares NOVICE and NOVICE/COMPT with the results 
of a non-linear regression program written by Yeh and Kwan (90). 
The data used was originally published by Wagner et a 1. (81) 
and is reproduced by Yeh and Kwan. Here, all weighting factors 
produced extremely high correlation coefficients, although the 
closest average drug levels (by percentage) were not reproduced 
by the model with the best correlation coefficient. Further, 
COMPT did not improve the average drug levels, although it did 
reduce the SS. All two-compartment models proved superior to the 
one-compartment model (found by SINGLE) as measured by the 
correlation coefficient and the average drug level difference. 
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TABLE IV 
Avg Level 
kl 2 k21 kel Vp CC SS dif f 
Yeh & Kwan 0.1 36 0.247 0.545 7.83 
NOVICE wt(l) 0.867 1.601 0.6 95 6.25 0.9989 
00 . t"- 
NOVICE/COMPT 0.835 1.541 0.669 6.67 
NOVICE wt(2) 0.867 1.601 0.695 6.25 0.9989 7.8 
NOVICE/COMPT failed to conve rg e 
NOVICE wt(3) 0.152 0.329 0.547 7.78 0.988 0.037 5.1 
NOVICE/COMPT 0.159 0.345 0.574 7.59 0.024 10.8 
NOVICE wt(4) 0.153 0.329 0 . 547 7.78 0.988 0.009 5.1 
NOVICE/COMPT 0.158 0.342 0.569 7.65 0.006 7.7 
SINGLE 0.936 16 . 5 
Units of kl2, k21, and kel are 1/hr. Units of Vp are liters 
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DISCUSSION 
A number of authors over the preceding twenty years have 
attested to the fact that drug doses and/or dosing schedules must 
be altered in patients with renal disease (4,16,17,79,81). In 
particular, Dettli et a 1. (16) developed detailed procedures 
for adjustment of drug dosage based on a patients creatinine 
clearence, whereby clinicians could calculate how changes in the 
glomerlular filtration rate (GFR) would alter the normal kel. 
The normal kel was determined by studies on populations of 
varying sizes; requiring, of course, a separate study for each 
drug. The primary difficulty here is that this "normal" kel 
represents an averaged figure and may well be incorrect for any 
given patient under consideration. Another problem, is that no 
provision is made for patients who might require altered drug 
dosing on a basis other than, or in addition to, renal disease; 
for example the patient with cirrhosis or congestive heart 
failure receiving a drug metabolized partly or in whole via an 
hepatic route. 
It is for these reasons that I developed NOVICE, wrote it to 
be used with a modified form of COMPT and LEVEL3, and made it 
accessible to individuals with little, if any, experience with 
computers and pharmacokinetics. It should prove particularly 
valuable when being used with a drug with a low therapeutic index 
where careful maintanance of appropriate blood levels is 
imperative. 
NOVICE was programmed to allow the user to have the option 
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of two-compartment pharmacokinetic simulation. The subroutine 
EQUATION contains most of the source code for this. It is 
anticipated that simulation will be used primarily by 
pharmacologists; applications would include the following: 
1. The prediction of serum blood levels with a given set of 
"estimated" parameters, thus enabling one to make 
educated decisions as to when serum blood levels should 
be determined in an actual pharmacokinetic experiment. 
Proper timing would insure that adequate numbers of 
blood samples are obtained from periods where there is a 
rapid change in drug levels (e.g., the "alpha" phase). 
2. The determination of the maximum amount of error that 
can be introduced into a generated set of data, while 
still enabling one to rederive the parameters used to 
produce the data. Researchers developing a drug assay 
would then know in advance the degree of precision that 
was required. 
3. The calculation (with the aid of LEVEL3) of a number of 
different dosing schedules based on the introduction of 
varying levels of error into a given data set. This 
would facilitate comparison of the effect of errors in 
drug assay on ultimate drug dosage. 
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NOVICE is designed so that non-linear least squares analysis in 
parameter estimation is not performed when the EQUATION mode is 
being used. This was done since non-linear regression, while a 
useful tool in data analysis, rarely produces changes greater 
than 20% in the parameter estimates — and usually produces 
changes far less — as was shown above. Since in this mode the 
data is generated from "theoretical" or "estimated" parameters 
(to which error is then introduced) there seems little need to 
further adjust the "preliminary" estimates of NOVICE'S 
curve-stripping. Indeed the EQUATION mode was not designed for 
exact parameter derivation from any given set of starting values 
and error. Its real purpose lies in comparing the differences in 
parameters calculated from the same set of starting values, and 
varying levels of error. 
There are, of course, limitations to the program(s): 
1. To use them, at least four (and preferably more for 
increased accuracy) serum drug levels must be available 
following a single drug dose. This could be a problem 
if serum drug determinations are inconvenient to 
perform, or, if in an emergent situation a loading dose 
and them maintanance doses of a drug must be 
administered rapidly without waiting for the appropriate 
blood samples to be drawn. 
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2. In a patient with fluctuating levels of renal function, 
the results of a trial dose and subsequent parameter 
determination may not apply the next day, as GFR's can 
change rapidly. This, of course, is a limitation with 
all computerized kinetic programs. 
3. Pharmacokineticists may not be interested in LEVEL3, but 
for clinicians it will be of primary concern, as it does 
the work of changing the data from kinetic parameters to 
a drug dosing schedule. However, this results in two 
problems. First, if peroral administration is the 
chosen route, there are no provisions for 
individualizing the fraction of a drug absorbed (Fabs) 
and the kinetic rate constant of absorption (Kabs). 
Instead, Fabs is assumed to be a bioavailability of 100% 
(although the user enter a different value), and Kabs - 
if not available from the literature - is set to have 
drug absorption at greater than 90% after one hour. 
These settings are obviously gross estimates but should 
prove adequate in most clinical situations. 
4. While adding COMPT to NOVICE always results in a 
reduction of the SS, it can take quite some time to 
achieve convergence (and convergence is required for 
non-linear regression to be completed). 
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Pharmacokineticists will likely be willing to make this 
sacrifice, clinicians may not. This is particularly 
true when one realizes that COMPT does not always give 
better results for drug levels, as measured by the 
average percentage of level difference. This can be 
seen in tables II and IV. A reduction is COMPT time can 
be achieved by choosing a larger CTF, or reducing the 
maximum number of iterations. Alternatively, the option 
is offered to bypass non-linear regression altogether 
and pass directly to LEVEL3. 
5. Use of LEVEL3 requires one to specify in advance a 
desired minimum and maximum serum drug level. For 
antibiotics this should be simple since minimum 
inhibitory concentrations are widely available, and the 
maximum level might be a factor of 8 to 16 times greater 
(a relationship perinent to serum bacteriocidal 
concentration). Even for other drugs this should not be 
a problem as most drugs for which an assay exists are 
also drugs for which optimum serum levels have been 
determined (e.g., digoxin, lithium, quinidine, 
theophylline, pentobarbital etc.). 
6. The ability of both NOVICE and NOVICE/COMPT to 
accurately derive the kinetic constants Alph a and 
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Beta is very much dependent on the magnitude of 
difference between them. Myhill et al. (33) found 
that with an error in data measurement of 2% they could 
resolve rate constants (with an accuracy of 10-15%) 
differing by a factor of two; with an error of 6% a 
ratio of four between costants was required; with an 
error of 10%, a ratio of six. While detailed studies 
such as these were not performed on this program, a 
similar trend was clearly noted. 
The flow-chart for the sub-routine CORRECT'BETA (figure 8) 
deserves comment. In either mode of operation it is required 
that all parameters be positive for a model to be considered 
acceptable. The justifications for this are primarily ones of 
tradition and reason. Many of the pharmacokinetic computer 
programs cited here (NONLIN and Muir's TI-59 program are 
exceptions) incorporate this criterion. Beyond this though, it 
would seem that any model used in calculations should conform to 
reality which obviously requires that once a drug is administered 
and fully absorbed the amount of drug present in the body must 
decline rather than rise. The reader should be aware however, 
that there is another school of thought. Smolen (8, p. 365) for 
example, has proposed that "[C]ompartment models are not 
necessarily unique and realistic descriptions of the biokinetic 
behavior of a system.. It is suggested that ... it may be 
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justifiable to abandon all pretenses of requiring compartment 
models to possess physical reality." (We often do abandon 
reality when we speak of the concept of a volume of distribution. 
For example, a drug with a long half-life, such as digitalis, 
commonly will have a volume of distribution far in excess of a 
patient's total body water.) 
In addition, in the EQUATION mode it is required that any 
model chosen have parameters within a factor of two of those used 
to generate the data. This criterion is necessary, because when 
blood levels are drawn close together — e.g., in the "alpha" 
phase — errors in the opposite direction in the drug 
concentration tend to be magnified by a small t in linear slope 
determination, such that the derived values for A and Alpha 
will be very different from the original ones. This is 
particularly true if the number of points in the "alpha" phase is 
small. For example, if the original data were: 
time = .1 hr level = 100 units 
time = .2 hr level = 200 units 
then the true slope, & level/2)time would equal 12.5 units/hr. If 
an error of say 20% is applied in opposite directions the levels 
at .1 and .2 hours might be 120 and 64 units respectively 
yielding a slope of almost 20 units/hr. These effects are 
consistent with the results of Myhill et a 1. (46) in their 
experiments on the introduction of random error into data 
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generated by a bi-exponential equation. 
The use of two as a cutoff factor is somewhat arbitrary, but 
may be justified as allowing enough parameter variation to 
tolerate errors of up to 20% (certainly within the limits of most 
laboratory assays (32)) but still rejecting models where 
parameters vary by greater than 100% from their original values. 
In the mode of existing data (HAVE'DATA) there is no analagous 
cutoff factor. 
Other major points to be addressed are the accuracy of 
NOVICE (and its combination with COMPT) as compared with other 
programs in existence, how best to use this program, and how 
confident may one be that its parameters can be translated into 
desired drug levels and drug doses. To treat these fully, one 
must understand the meaning and use of weighting factors. 
Ideally, in curve fitting, a value for an observation at any 
given time should be assigned a weight inversely proportional to 
its variance (54,57). Thus, " [i]f the reproducibility of the 
estimation of any variable at any sampling point is bad . . . the 
large variance at that point automatically ensures that the local 
normalized sum of squares will be small, i.e., that sample will 
not play a large role in determining the final fit." (54, p. 730) 
Unfortunately, in the vast majority of cases, data used here 
will provide only single observations at each sampling point and 
thus no variance is available. A number of solutions have been 
devised for this problem, none totally sataisfactory. Some of 
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the more complex have involved division of each data point by the 
lowest data point in each equation (46) , or attempting to 
calculate an estimated variance equal to the residual sum of 
squares divided by the residual degrees of freedom (the latter 
being the number of data points minus the number of parameters to 
be estimated) (57) . 
Ottoway (54), in a detailed discussion of data weighting 
felt that (based on extensive testing) the rather empiric factor 
of 1/(C + C')2 produced the best results. (Here C is the 
actual measured serum drug level, and C' is the value calcuated 
using the set of derived constants). When error was constant 
1/(C + C')2 became functionally equivalent to 1/(C)2. With 
this in mind, the user of NOVICE/COMPT has been offered the 
option of weighting data by a factor of 1 (i.e., unweighted), 
1/C, 1/ (C)2 f or 1/(C + C')2. The latter two are strongly 
recommended, however the first two options might be more 
desireable if for some reason one wanted to give greater weight 
to numerically higher results (e.g., if an assay was inaccurate 
at low levels) . 
While the SS gives a rational basis for choosing the best 
model within a given weighting scheme, it offers no clue as to 
which best model between weighting schemes should be used, 
since interscheme variation in SS depends upon data values and 
not just goodness of fit. There is no such interscheme 
variability with the correlation coefficient; this parameter can 
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therefore be a valuable guide in choosing between schemes. 
Indeed in Table II, the model with the best correlation 
coefficient was always the model with the lowest average level 
I 
difference. However in Table IV, that relationship did not hold 
! in every case, which may attest to the fact that both the 
correlation coefficient and the average level difference are 
imperfect guides to goodness of fit. Other guidelines might be 
accuracy of the assay as suggested above, or desired serum blood 
levels i.e., very high or rather low. When inis doubt with such 
conflicting results, Ottaway's suggestion of 1/(C + C')2 as a 
weighting factor would probably be the most sensible choice. 
Addressing the issue of translation of calculated parameters 
into accurate dosage recommendations, NOVICE/COMPT has 
demonstrated its ability to derive parameters which can be used 
i 
to predict durg levels consistently within 20% of their true 
values, and generally well within 10% (see Tables III and IV). 
Certainly this is within the range of acceptable error for all 
drugs used and comparable to the error inherent in most drug 
assays (69). However, the caveats above still apply (especially 
with regard to Kabs and Fabs, and changes in renal function). 
The question remains of NOVICE/COMPT's performance vis a vis 
other similar programs. With some data and programs its results 
are impeccable (Table I), with others quite good (Tables II and 
IV) and with still others, poor (Table III), at least as regards 





drug levels is the ultimate criterion, then even results such as 
those in Table III are adequate. In any case, to judge one 
program by another is a questionable process since it implicitly 
affirms the validity of the original program by holding it up as 
a "gold standard." There can be little basis for doing so. SS's 
can be compared, but only if the same weighting system is used. 
Even NONLIN reached convergence on a negative parameter value 
(Table III) and can produce huge (>100%) standard deviations. 
Indeed the authors of that program have stated "We have little 
interest in comparing the performance of different computer 
programs on one set of data. We have often said that given two 
computer programs A and B ... we can find two sets of data, set 
I and set II, such that program A is 'better' with set II and 
program B is 'better' with set I." (43, p.445). Other problems 
with COMPT e.g., failure to converge with one set of data with a 
given weight (see Table IV), and dependence of accuracy on 
initial estimates are "common to all Gauss-Newton-based programs 
to a greater or lesser extent." (44, p. 13, 77) 
Some pharmacokinetic programs are designed to fit a given 
set of data to a multi-compartment model with the ultimate number 
of compartments in the model to be determined by whatever number 
yields the "best fit" (in accordance with a pre-spec ified 
criterion of "goodness of fit"). However, it has been stated 
that most pharmacokinetic problems can be solved adequately with 
a two or three compartment model (70). For simplicity's sake, 
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and because NOVICE is designed for relative novices, three 
compartment models are not considered. The pharmacokinetic 
purist may find this unsavory 84, p. 448) but I believe the 
sacrifice in accuracy is well worth the gain in simplicity and 
ease of understanding. In further defense, it should be noted 
that using the same set of data, different programs can fit the 
set to models with different numbers of compartments. Nagashima 
et a 1. (47) fit IV Coumarin to a three-compartment model, while 
Yamaoka et a 1. (89), using the same data, arrived at a 
two-compartment one. A graphical analysis (89) of actual serum 
drug levels versus those predicted on the basis of either model 
indicate that the primary difference is in the terminal points 
(i.e., those at very low serum levels) when the three-compartment 
model exhibits a "gamma" phase non-existent in the two-compatment 
one. Similarly in simulated three-compartment data with 5% error 
(89) again the major predictive differences are at the terminal 
portion of the curve. (In stark contrast, a single-compartment 
model produces a curve with significant variations from the two- 
and three- compartment models at all drug levels (24)). To the 
clinician variations at the end of the curve should make little 
difference as this section of the curve represents extremely low 
serum drug concentrations and most patients will be maintained on 
much higher drug levels. These higher levels will fall in 
mid-range of the curve being used for analysis. Regardless of 
whether a two— or a three-compartment model is being used the 
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mid-range of the curve is the most accurate section since the 
early alpha phase may contain large errors due to problems of 
closely spaced samples (as discussed above) and the terminal 
portion of the curve is affected by the difficulty of performing 
an assay when the drug concentration is very low. 
COMPT was chosen as the companion program to NOVICE simply 
because its source code was in the public domain, and available 
rapidly as it had been reprinted in the original publication 
describing the program (1). It was fortuitous that its 
facilities matched well with those planned for NOVICE. The only 
major difficulty was translating from one superset of BASIC to 
another and writing the necessary additional subroutines. 
In summary, I have written a new computer program called NOVICE 
to perform two-compartment pharmacokinetic analysis in a manner 
both understandable and useful to the working clinician. It was 
designed for integration with COMPT, a non-linear least squares 
regression analysis program, and LEVEL3, a program to determine 
drug dosing using two-compartment parameters. NOVICE performs 
curve peeling in a highly interactive fashion, allowing the user 
to select various weighting factors, make appropriate 
interconversions, and view detailed statistical analyses. NOVICE 
may be used for simulation or with clinically derived data. 
Simulation will be of interest to the pharmacokineticist who 
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wants to predict in advance when to draw blood samples in an 
actual experiment. It will also prove useful to the clinical 
chemist who needs to know what degree of accuracy he/she must 
achieve in a drug assay. Using "real" data with the program, the 
clinician can determine any patient's two-compartment 
pharmacokinetic parameters for a given drug (with the aid of 
COMPT) and then using LEVEL3 translate these into an exact dosing 
schedule based on desired maximum and minimum blood levels. 
Studies show this combination of programs is able to perform 
pharmacokinetic calculations which predict drug levels accurate 
to within the confidence limits of the great majority of drug 
assays. 
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For the two-compartment open model which is the focus of 
this paper and was shown in figure 2, the appropriate 
differential equations (adapted from refs.35 and 10) are: 
V1*dc1/dt = -V1*kl2* ( C^-C^) - V2*kel*C1 (#A1) 
V2*dC2/dt = V1*kl2*(C1-C2) (# A 2) 
where = volume of compartment #1 (central compartment) 
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and 
V2 = volume of compartment #2 (peripheral compartment) 
C^ = concentration of the drug in 
C2 = concentration of the drug in V2 
kl2 = first order rate constant representing the fraction 
of the drug being instantaneously transferred from 
compartment #1 to #2 
kel = first order rate constant representing the fraction 
of the drug being instantaneously eliminated from 
the system via compartment #1 
Vd = the steady state volume of distribution = V, + V„ 
ss ; 12 
Integration of the equations yields: 
and 
Cn = A* e + B * e 
C„ = 
_CS*4- 
A ' * e + B ' *e- /3*t 
( # A 3) 
(#A4) 
where Be ta < Alpha, by convention. 
Of interest to us is equation #A3 because its left-hand 
side, C,, is an easily measured quantity, namely serum drug 
level. Unfortunately, equation #A4 is of much less value. C2> 
a tissue drug level, is not so simply obtained. 
To solve for each of the constants in terms of the others we 
obtain the well known relations: 
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(k 12 + kel - /3 ) * (C, ) 
A = -  t=0 (#A5) 
(«“(>) 
(k12 + kel -^ *(C ) 
B  -1 t =0 (#A6) 
(/3-<*) 
where C^ at time t=0 equals A + B. 
Rearranging yields: 
k 12 = (A*<* + B*/*)/(A + B) (#A7) 
kel = (A + B) / (A */S+ B *^) (#A8) 
Vj. = D/(A+B) (#A9) 
V2 = V1 * (kl2 * kel)/(^*^) (#A1 0) 
= V, * (kl2/k21) 
Thus Vd (ss) , the volume of distribution of the entire system at 
steady state, is: 
Vd (ss ) = V1 + V2 = V1*(l + k 12 /k 21) (#A11) 
And, 
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^ = (b + sqr(b2 - 4*c))/2 (#A12) 
/3 = (b - sqr (b2 - 4*c))/2 (#A13) 
b = kl2 + k21 + kel (#A14) 
c = k21 * kel (#A15) 
where sqr is the square root function. 
Using these formulae, when A, Alpha, B and Beta are 
obtained (by whatever means), kl2 is found with equation #A7, kel 
with equation #A8, and k21 is derived as follows: 
Since, 
D (k21-*) D (k21-/3) 
C, = - *-* e + - *-* e (# A16) 
V ((*-*) V (~-/3) 
after a sufficiently long period of time has elapsed, the first 
term has a negligible contribution and a straight line through 
the graph of log C^ vs t can be drawn. This results in a plot 
whose y-intercept is: 
B = D * ( k 21 ) / V ^ * (<* -ft) (#A17) 
Similarly, the y-intercept of the other component of the 
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biexponential is: 
A = D* (k21-*)/V* (^-*) (# A18 ) 
From equation #A9 D/V^ = A+B and thus equation #18A reduces to: 
A = (A+B)*(k21 -#)/((!-*) (#A19) 
We can now solve this for k21: 
k 21 + A* (r3-<*) / (A+B) (#A20) 

APPENDIX B 
The method of least squares is designed to fit a function to 
a given data set so as to minimize the error, where error is 
measured by the sum of the (weighted or unweighted) squares of 
the residuals from the difference between the actual data point 
and a function-derived "calculated" point (at any given value of 
the independent variable) . 
Thus, from Draper and Smith (21, p.9-11), if we measure 
values for a variable Y, and propose that they are a function of 
the variable X, then Y' = b^ + b^*X where Y' is the 
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"predicted" (or "calculated") value of Y for a given X. The 
residual then for any given point is: 
Y. 
1 - b0 “ bl*Xi 
( # B1) 
and the sum of the squared residuals SS is: 
n 
SS = 2 (Y. - b - 
i = l 
bl*Xi) (#B2 ) 
To minimize this function one need only take the first 
derivative(s) and set it (them) equal to zero, as below: 
and 
n 
SS/ b = -2 £ (Y. - bQ - b1*X.) = 0 
i = 1 
n 
SS/ bx = -2 ^(X.)*(Y. - bQ - b1*X.) = 0 i _ 1 
(#B 3) 
(#B4 ) 
These expand respectively into the so-called "normal" equations 
of the system: 
b0*n + bl* Xi = Yi (#B5) 
v xi + bi* (xi } = xi*Yi (#B6) 
which can them be solved as two equations in two unknowns for 
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and , in terms solely of and Y^. 
This basic approach, i.e., a solution through the normal 
equations, will work for all linear systems and can be adapted 
iteratively for some non-linear systems as well. With the 
particular non-linear system we are considering, an attempt (not 
shown here) to derive normal equations arrives at this equality: 
e-°<*t*e-/3*t (#B7) — * t c- * t 
(1/B) * (£Y*e L - A*Se * e 
The next step is to solve this equation for Beta. 
Unfortunately no explicit solution can be found thus this method 
will fail. 
The most commonly utilized alternative is the Gauss-Newton 
method or a modified version thereof. A non-linear estimation 
using this approach is complex; it will be more easily 
understood if we first apply the method to a linear solution. 
(The following, known as Gauss elimination, has been adapted from 
Ho rnbeck (31)) . 
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X22 X23 j ] b2 | = | Y2 | 




 1 X32 X33 Lb3J Ly3J 
When the top row o f the matrix is divided by we get: 
r 1 
| X12 ' X13'~! ! bi~! 
l~YlT! 
j X21 X22 X23 j ! b2 j ■ I v2 j (# B12) 
1 —X 31 X32 X33 
l_b3_l 
1 _y 3-1 
where a prime (') is used to show that the original element has 
been changed arithmetically. The first row is now multiplied by 
X2^ and subtracted from the second row yielding: 
r 1 
1 X12' X13 * j !-YiT! 
1 o 
1 X22 * X23 ' j | b2 | - 




 1 X32 X32 Lb3J 1 —Y 3—1 
Repeating this sequence with the first and third rows gives: 
r i 
i X12' X13j j-bi~j i~YiT! 
1 o 
| X22' X23' j ! b2 | ■ | Y2 ' J 
(#B14) 
L 0 x32' x33- 1 '-b3-' LV1 
If the second row is divided by x22'. multiplied by X^2* anc3 
subtracted from the third row, we obtain: 










X23' 1 1 b_ 1 1 | Z | [ Y 2'! 
(# Bl5) 
1 o 0 X33' J l_b3-' ' —Y 3 ' 1 
Elements already changed from their original values, and thus 
marked "prime" have not been double- - or triple-primed even if 
they have subsequently been changed in value again. 
Finally the third row is divided by X^' yielding: 
r 1 
| X12 ' X13 ' [ 
l“b “| 1 ~Y T| 
I I I I 
! 0 
| 1 X23' | 
1 b„ | = | Y ' | 
I I I I 
(# Bl 6) 
1 0 0 1 _| l_V' 
The final row is now equivalent to b^ = Y^' and thus b^ is 
solved for. Substituting into the second row: 
fc>2 + x23 * *b3 = y2' (#B17) 
will then give b2; and b^ is similarly obtained. 
(Actually, the final substitutions can be compacted into further 
matrix manipulation, giving as a final result: 
II 0 0 
I 
10 1 0 
I 
10 0 1 
I b. 
'-b3- 
double primes indicate that the values 
been changed from equation #B15. This 
I Y1 " 
I Y ' ' I 
I 2 I 
i-V 
(# B1 8) 
of Yi through Y^ have 
method - Gauss-Jordan 

t 
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elimination - is the same as Gauss elimination in principle but 
derives the identity matrix at the end, thus dispensing with the 
need for substitutions.) 
The process outlined above can be represented as: 
X * B = Y (# B19) 
where capital letters stand for matrices. Obtaining the final 
solution, or solving for the b's is then a matter of deriving: 
B = (X)-1 * Y (# B20) 
Here, (X) ^ is the inverse matrix of X such that X * X
 i 
yields the identity matrix. 
If the system to be solved is (adapted from 4): 
Y. = b *X.. + b *X0. * b *X,. 
l 111 2 2l 3 3l 
(# B21) 
then to minimize the sum of the squared residuals (SS) where 
n ~ 
SS = Z (Y. - Y') 
i =1 
(# B2 2) 
we obtain the normal equations represented by: 
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j"Xli2 Xli*X2i X1 i*X3i j ' q i | xii*Yi ~] 
[ X1i*X2i X2i2 X2i*X3i ' 
1 1 1 
j b2 j " | X2i*Yi j (#B2 3) 
1- X1i*X3i X2i*X 
X ^ 1 
3i 3i 
1 1 ! 
LV L X3i*Yi -1 
or: 
(X' * X) * B = X' * Y (#B24) 
where X' = the transverse matrix of X. Here: 
X “ xn x 2i X3i -1 (# B 2 5 ) 
!' xif' 
X ' 
- | X2i | (# B26) 
L x 3 i_ 1 
!‘brj 
B = 
! b2 ! (# B27 ) 1 1 
Lb3_l 
and Y [Yj] (#B28 ) 
So that B = 
-1 
(X1 * X) * (X' * Y) (#B29) 
In the linear system specified by equation #B21 the normal 
equations are also linear, and thus equation #B29 is singlularly 
soluble. However, as Muir (44) has stated, "[T]he normal 
equations describing the least-squares fit to a nonlinear system 
are also nonlinear in the parameters and there exists no direct 
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solution for the minimum (and unique) sums of squares. Thus 
iterative techniques are invariably employed in any attempt to 
solve them." 
The Gauss-Newton (or Taylor series) method "linearizes" the 
function via a first-order Taylor series approximation using 
initial parameter estimates, and then iteratively corrects these 
estimates. Linear normal equations can then be derived. 
For example, with equation #4 in the text rewritten as: 
-/3*t. 
Cp. = Ae l + Ee l (#B30) 
to indicate that it is in fact a summation of observations, a 
first order Taylor series expansion is: 
_°<*t — /3 *t 
Cpi = h * e 1 i + B1 * e ' 1 i + (#B31) 
(A' - A1)*(BCp./3A1) + (<*' - ^1)*(<?Cpi/5^1) + 
(B* - B1)*(5Cpi/dB1) + (p' - pi)*(dCpi/df*1) 
A prime denotes a "theoretical" true regression-obtained value 
for a variable; a numerical subscript, an approximation 
(i.e., A^ is thus the first approximation of A'). 
Since the first calculated value is 
_o(*t —fi* t 
C'p. = A * e 1 i + B * e ' 1 l (# B32) 
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then: 
CPi - C'p. = (A' - A1)*OCp./aA1) + 
(<*' - «x)*(acpi/a^1) + (#B33) 
(B' - B1)*(acp./«5B1) + 
(^' -^1)*OCpi/3^1) 
This is of the form 
Yi = b1*xli + b2*X2i + b3*X3i + b4*x4i (#B3 4) 
and can be solved as outlined in equations #B22 - #B29. 
For a variable V, the first iteration solves for (V' - V^). 
being the first approximation, is known, and thus V2 = (V' 
- ) + V^ is used as the second approximation, and the 
iteration is repeated. "Since the first-order Taylor series 
approximation of the fuction in the region of the initial 
estimates is not exact" (4), V^ = (V' - V^) + will not 
actually equal a true V' but will be an improved estimate. 
This procedure is repeated until successive iterations 
satisfy the convergence testing factor. 
Actually, the non-linear regression program used here, COMPT 
solves the model via equation #A16 using #A11, #A14 and #A15 for 
substitutions and thus obtains its results in terms of kl2, k21, 
kel and Vp. A, Alpha, B and Beta are then derived from 
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I 
I 
equations #A12, #A13, #A17 and #A18. Wong et.al. (87) has 
demonstrated that this method yields equivalent results to 
solving directly for A, Alpha, B and Beta and then 
calculating the other set via methods discussed above. 
Readers who desire more detailed information concering 
COMPT, including a flow-chart, program Using and description of 
how the partial derivatives are calculated are urged to read the 
original reference. However, an abbreviated explanation of the 
program can be found in Appendix D. 

APPENDIX C 
As an example of how similar drug levels and SS's can be 
obtained with one weighting system by quite different parameters, 
the EQUATION mode of the program was executed using data from the 
literature (18) for penicillin G with 1/(C1 + C)2 as a 
weighting factor, and a maximum deviation of 10%. With this 
input a trial run generated data whereby a "beta" phase of eight 
(of ten) points was chosen by the program as the best model with 
an SS - 0.004038. The next two closest models made use of "beta" 
phases of seven and four points with SS's of 0.004839 and 

0.004234 respectively. Table Cl compares the two best models. 
It is easily appreciated that the major difference in the 
parameter sets is between A's and Alpha's, since the calculated 
drug levels vary from each other most in the "alpha" phase and 
early "beta" phase (when these two coefficients exert their 
greatest numerical influence on the calculated levels). 
Note, though, that while three of the four parameters in the 
two models vary by greater than 5%, none of the calculated drug 
levels do. 
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TABLE Cl 
"Beta" Phase 
8 7 % difference Input Values 
ss 0.004038 0.004234 4.6 
A 0.1325 0.2071 36.0 0.146 
Al pha 24.84 60.57 60.0 5.80 
B 0.9018 0.8960 6.4 0.853 
Beta 1.010 1.007 0.3 0.996 







1.008 1.4 1.004 
0.016 0.9776 0.9623 1.6 0.9776 
0.031 0 .9 348 0.8994 3.8 0.8976 
0.063 0.8748 0.8460 3.3 0 .9178 
0.125 0.8008 0.7900 1.3 0.7415 
0.250 0.7009 0.6965 0.6 0.6787 
0.500 0.5444 0.5415 0.5 0.5664 
1.000 0.3286 0.3272 0.4 0.3198 
2.000 0.1197 0.1195 0.2 0.1143 
4.000 0.0159 0.0160 0.3 0.0164 
Note that in the "Given" levels the drug concentration is greater 
at 0.063 hrs than at 0.031. This is an artifact produced by the 
random error generator. Such error is found in real data too 
(see ref. #73, Table I, subject B.G.). It is taken into account 
in parameter calculation, but of course not reproduced in levels 
generated by those parameters. 

APPENDIX D 
While a full explanation of COMPT is beyond the scope of 
this paper, a few salient points are in order. First, as was 
mentioned above, the program has been modified for use with 
NOVICE. The changes introduced included the addition of new 
subroutines, (necessitated by the use of a slightly different 
programing language), changes in data input and output, and the 
provision for variation in the weighting scheme. 
Second, the program's actual algorithm uses a modification 
of the Gauss-Newton method, proposed by Hartley (30). Briefly, 
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Hartley's procedures is used to correct the estimations when they 
are in the neighborhood of an SS minimum by approximating the 
function as a quadratic and then interpolating the quadratic 
function to locate the minimum. A detailed description can be 
found in the original paper (30). 
Third, once a solution has been interatively converged upon 
so that the CTF is satisfied, a direct search of the parameter 
space (defined by the space limit vector - see below) is 
performed to insure that the solution was a true (i.e., global) 
minimum and not a local one. This direct search, a relatively 
time-consuming process, divides the parameter space into 100 
equal intervals and varies each parameter individually thoughout 
while testing whether any of these new parameter combinations 
results in a reduction in the SS. If not, the solution 
previously converged upon is considered a global minimum and the 
search is terminated. If however a new combination with a 
reduced SS is found then _i_t becomes the set of so-called 
"initial" estimates for a new set of iterations, (and the 
interation counter is reset at zero). 
(The parameter space limit vector is a constraint imposed on 
the parameter values (i.e., kl2, k21, ke, and Vp) to facilitate 
speedy solution of the model and help prevent divergence of 
solutions. In the case of COMPT any new estimates of the 
parameters must be within a factor of ten of the initital 
estimates. This factor was a somewhat arbitraty choice in the 
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original program but testing showed 
resulted in no reduction of SS, and 
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Here, double lines have been used to indicate the somewhat 
altered flow chart of NOVICE when it has been re-entered via 
COMPT as opposed to being run de-novo. 
Note that a few branch points having to do with error 
trapping during data input have been omitted from this flow 
sheet, and can be found in figure #5. Flowsheets for individual 
subroutines (here capitalized and underlined) can be found in 
figu res #6-8) . 
In addition, the user may reset the weighting factor even if 
non-linear regression was not requested. This is not shown in 




Data Entry Flow Chart 

Figure #6 
Flow Chart for CALC'BETA 
END of routine 

Figure #7 
Flow Chart for CORRECT'BETA 
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Are there only 
4 data points? 
Are there only- 
5 data points. 
N 
Beta phase = last 2 
alpha phase = first 2 
SS less for beta"'--N 
phase of 2 than of 3? 
Beta phase is last 
points 
Beta phase is last 3 
points 
Set standard values for 
parameters to input values 
if EQUATION mode in use, 
or equal to parameters of 
model where beta phase equals 
last 2 points, if HAVE'DATA 




Flow Chart for CALC 1 ALPHA 
Note, the final 
yield identical 
model was being 
now as previous 
storage space i 
linear regression on the "alpha phase" should 
results as that performed in CALC'BETA when the 
considered in that routine. It is recalculated 





2 COMPARTMENT PARAMETER TESTING 
copyright (C) 1982 
Laurence A. Turka 
all rights reserved 
you need directions? Y 
ese are the detailed directions for this two compartment 
armacok inetic parameter program. As you are probably aware, 
st recommended drug dosages are calculated from pharmaco- 
netic constants derived from pooled population data. While 
most clinical situations this is probably adequate to enable 
e clinician to feel assured that his/her patient is indeed 
ceiving a reasonably correct dosage of a given drug to main- 
in intended blood levels, there will be occasional exceptions 
this. Most commonly these will occur in the patient with 
tered renal function, although congestive heart failure and 
patic insufficiency are other frequent causes. Additionally, 
en administration of a drug with a very low toxic/therapeutic 
tio is being considered, a need for this program may arise. 
states of decreased renal function the clinician can use 
rmulas that calculate altered dosage and dose intervals 
compensate, however these formulas universally assume a one 
mpartment pharmacokinetic model, a state which in reality 
rely exists. For some drugs this will only result in minor 
rors for dosing, however for other drugs errors in the range 
50% will occur. 
ess <RETURN> to continue: 
particular if the drug is one that will be administered 
ironically and which has a low therapeutic index — e.g. 
goxin or theophylline — then it may well be worthwhile 
i derive an individual patient's own two compartment kinetic 
irameters to enable you to individualize your dosing scheme 
>r that particular patient. This program is designed to 
• do that for intravenous medication. It can also be of 
msiderable use if the drug is to be given per-orally, 
•iwever, it will not produce as accurate results. This 




he program may be run in one of two modes, 'EQUATION' or 'DATA', 
he latter is the mode of deriving the kinetic constants for a 
rug and is the one of interest for most clinicians. To use the 
rogram in this fashion you need to administer orally or by IV bolus 
he drug of interest, and subsequently draw a minimum of four, but 
referably more, serum blood levels. At least two of these blood 
evels should be drawn within the first 15 minutes after the drug 
as been given. The remainder can be after any reasonably length 
f time has past, (e.g. — 3 and 6 hours) and can be done at your 
onvenience. When you run the program you will be asked what drug 
ou are going to be using, and if this drug is known to the 
irogram library, it will make suggestions as to appropriate times, 
ress <RETURN> to continue: 
Whichever drug route you choose should be the one by which 
/ou plan to administer the drug chronically, and the one for 
rfhich you are using this program in the first place. 
However, please be aware, that calculations for IV adm in i s ta t i on 
i(ill be more accurate than those for PO, as in the latter case 
a population derived averaged constant of absorbtion will be 
used to calculate the rate by which the drug is absorbed from 
the GI tract. In the case of the IV route, this inaccuracy will 
not need to be introduced. 
This program will first give initial data results using a 'curve¬ 
peeling' technique, and then use these initial estimates for the 
more sophisticated non-linear regression estimation. During the 
j the latter there will be a series of revised estimates for the 
parameters printed on the screen as the program cycles through 
each iteration. The full process can take quite some time, so 
please be patient. 
Press <RETURN> to continue: 
The 'EQUATION' mode will be of interest to pharmacokineticists 
In this option mode you will be asked to specify the 
i four parameters (A, Alpha, B and Beta) of 2 compartment 
i pharmacok inet i cs. You will then be able to simulate the IV 
administration of a drug, during which 10 blood levels will 
be drawn for you at appropriate intervals. These so-called 
'perfect' levels will correspond exactly to the parameters you've 
entered. You will be asked to specify a percentage of random error 
to be introduced, and the computer will do so and then use its 
curve peeling routines to try and rederive the initially 
entered parameters. From these it will arrive at 'calculated' 
levels for the drug at the various sampling times. Its accuracy 
in reproducing the parameters is a function of their relationship 
to each other, the amount of random error chosen, and of chance 
in that a given amount of error has different effects at various 
sampling times depending on the interval between them. f 
Note that non-linear regression is not run in the 'EQUATION 
node as the initial estimates of curve peeling are sufficient 
for the purposes of the simulation. 
^ess <RETURN> to continue: 

ManyPquesti.ns 2 P°‘"tS ""d 
answers. If they are correct iust hi i- ^ 1°wed .bV anticipated 
not, just type in the correct oJe wJich w ^ r\turn' if 
With regard to data entry you mav Mihor .-11 erfse the first one. 
line by line at the tim^youar^r ^Pe the data in 
ably for you — you may create a fe Pro9rani> or prefer- 
||: ex tens ion LST and enter the data into the°filef n3me' WUh the 
To do the latter type VUE DATA! r^T cnKe«-««. • 
digit number of your choice for'thl fS ^ !r l“0 
unfamiliar with computers or data r.n 1 ► V u are totally 
discretion being thS ^^0^1 o * 
.uch easrer to just enter the data as the progllm rjnsf 
bestapossible"curvento^the dljf^"9;/" td “* '»• 
numerleal weight to assig^ tf deC‘de 
Press <RETURN> to continue: 
There are several options which it will present to you, one of 
equal weights (1), one of weighting by the inverse of the actual 
data point (1/C), one weighted by the inverse squared (1/C**2) 
and one of the inverse of the square of the sum of the actual 
point and the calculated point (1/(C+ C')**2). Recommended 
choices are equal weights if the drug levels vary by an order 
of magnitude or less, and (1/(C + C’)**2) if they vary by 
more than an order of magnitude. We STRONGLY urge that if 
you are unfamiliar with data weighting you use one of the 
latter two methods. 
Press <RETURN> to continue: 
Anally, a 1 ittle explanatory note on non-linear regression. 
The last information you will be asked for is the convergence 
and number of iterations you desire. If you are unfamiliar with 
these terms they may be thought of as the criterion which you 
use to decide if a good model has been chosen, and the number 
of times that you want to cycle through the program, making 
adjustments in your model, until the criterion is filled. 
Default answers have been provided and I suggest you use them 
unless you know what you are doing. In any case the amount of time 
this phase of the program takes to run is inversely proportional 
to the size of the convergence, as is the accuracy of the model. 
The number of iterations has much less effect on the run-time 
and is best left alone. 

Enter 1 for simulation, 2 for your own data: 2 
Will you be wanting non-linear regression analysis? Y 
Data is available for simulation and/or comparison 




























If you are using data of one of these drugs, I will compare your 
parameters values with those stored in my memory once calculations 
are complete. 
Press <RETURN > to continue: 
Is the data already in a file? Y 
Filename? YEHX8.LST 
Was the drug given P.O. or I.V.? IV 
What is the name of the drug? SPECTINOMYCIN 
Is the data already in a file? Y 
Filename? YEHX8.LST 
Was the drug given P.O. or I.V.? IV 
What is the name of the drug? SPECTINOMYCIN 
The drug you are studying is not in my library and therefore 
I will be unable to help you with comparisons of the results 
of your data and population studies. As this comparison serves 







of units for dosage in 
(3 ) , and 'units' (4 ) . 
grams (1) mill ig rams 
would you like to use (code number 1 to 4) 2 
(2), 
Using the units that 
what was the dose of 
you have just selected, 
the drug? 500 
1 = mg/dl 
2 = ircg/dl 
3 = ng/dl 
4 = mg/ml 
5 = mcg/ml 
6 = ng/ml 
7 = units/ml (e.g. - for Penicillin) 
What units do you use for serum levels 
If you are using your own data, these units 
MUST be the same as the input levels. 5 
The units that you have chosen to use for both dose 
and serum levels will be retained throughout the entire 
program, but used only in dosage scheduling. In the other 
tables that appear, drug levels are in mcg/ml. 
Should you be using a dose in 'units', then in tables, 
levels are in units/ml. 
Rate constants are in units of 1/hr for 
alpha, beta, kl2, k21, and kel. 
They are in mg/hr for A and B 
Volumes are in units of liters. 
Weighting factors are set by the user. For equal 
weights type 1, for 1/C type 2, for 1/C**2 type 3 
for (1/(C+ C ' ) * *2) type 4. 
Here, C = the actual experimental or random generated drug level 
and C' is the calculated level. 
Again, if you are not familiar with data weighting we UFCE you 
to pick option 3 or 4 (the latter is especially recommended). 
The desired weighting factor for error minimization is: 3 
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I now require additional 
regression portion of the 
directions. 
information for the non-linear 
program, as was explained in the 
What is the convergence testing factor? .000001 
What is the maximum number of 
iterations to be used? 1 
My analysis yields 2 
number for the 'beta' phase. 
points as the correct 
Using this: 
Beta= 0.22366 and B = 11.67066 
The standard error of Y= 0.00000 
Using the remaining 6 values to calculate 
ALPHA and A, I obtain: 
A1pha= .804431 and A = 52.6153 
The standard error of Y = 610.981 
Would you like to see the model chosen? Y 
Calculated A 52.615301 
Calculated Alpha = 0.804431 Num'levels = 2 
Calculated B 11.670663 Weight = (1/C)**2 
Calculated Beta = 0.223656 
TIME (HRS) GIVEN LEVEL CALCULATED LEVEL 
0.167 63. 3000000 57.2558304 
0.333 50. 6000000 51.0734615 
0.500 43. 3000000 45.6269186 
1.000 31. 0000000 32.8687958 
2.000 18. 3000000 17.9906894 
4.000 6. 9000000 6.8775487 
6.000 3. 0500000 3.4716498 
8 .000 1. 9500000 2.0343785 
The weighted sum of the squared residuals = 0.037007 
The correlation coefficient = 0.988024 
Press <RETURN> to continue: 
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ould you like to see the preliminary distribution constants? Y 
K12 = 0.15229 1 
K21 = 0.329092 
Kel = 0.546705 
Vp = 7.778 
'ress <RETURN > to continue: 
(ould you like to reset the weight? N 
!*he program will now shift into its non-linear regression phase 
fou are allowed only one weight in the interests of time and to 
>et this weight it is necessary that you re-select it unless it 
ias your previous choice. 
four previous weight choice was 3 
This corresponds to a weight factor of (1/C)**2 
Is this the scheme you want to use? Y 
STARTING ESTIMATES FOR THE ITERATIONS 
K (10) ITERATION K (1 2) K (21) 
1 .152291 .329092 .546705 
2 .160857 „ .347603 .577456 
3 .160697 .347256 .576881 
4 .160516 .346867 .576234 
5 .160318 .346439 .575523 
6 .160114 .345997 .574788 
7 .159938 .345617 .574158 
8 .15987 .34547 .573913 
9 .159866 .345462 .573899 
10 .159864 .345457 .573892 













12 .159862 .345453 
.5 7 38 8 6 7 5 8 6.03 
13 .159862 .345453 
.573884 7586.06 
The non-linear regression phase of the program has been completed 
You will now have an opportunity to view the finalized data 
and the many parameters automatically calculated for you. 
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£ter 13 iterations, convergence = 




Estimated Standard 95% 
va lu es D evia t i on 
Confidence (By group o 
Limits (Independently 
K12 0.1599 0 .0 340 0 .0278 TO 0 .29 20 ( S) 
0.0180 TO 0.3017 (U) 
K21 0.3455 0 .128 1 -0 .1 520 TO 0 .8 429 (S) 
* -0.1888 TO 0 .8797 (U) 
Ke 1 0.5739 0 .0205 0.4943 TO 0 .6 5 3 5 ( S) 
0.4884 TO 0 .6594 (U) 
Press <RETURN> to continue: 
Volumes of Distribution 
V' TOTAL- 2.161 V' CENTRAL= 7586 .070 V' PERIPHERAL3 3510.5 35 
V( STEADY STATE) = 11096 .6058 
Half Times 
T( 12) = 4.3350 T( 21) = 2.0061 T(el)= 1 .2076 






TIME ( HRS) GIVEN LEVEL CALCULATED LEVEL 
0 .167 63 .30000 64 .98073 
Calculated A = 
Calculated Alpha = 




























fould you like to see the final distribution constants? Y 
K12 = 0.1 5986 2 
K21 = 0.3454 52 
Kel = 0.573884 
VP 7.586 
Press <RETURN> to continue 
Spectinomycin blood levels are usually measured in units of mcg/ml 
— are these the units you are accustomed to using (Y or N) ? Y 
Spectinomycin doses are usually measured in milligrams 
— are these units satisfactory (Y or N) ? Y 
Spectinomycin formulated for IV usually has 
a bioavailability of 100 % 
— does the preparation of spectinomycin which you are using 
have a similar bioavailability (Y or N)? Y 
Would you like a dose schedule based on desired blood levels (Y or N) ? Y 
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enter desired maximum serum level of s pect i no my ci n in mcg/ml: 64 
Enter desired minimum serum level of s pect i no my ci n in mcg/ml: 1 
Assuming that the patient does not handle spec t ino my ci n in 
an unusual fashion, the foLlcwing doses and dose interval are 
recommended to achieve an equilibrium serum minimum of 
1 mcg/ml and an equilibrium serum maximum of 64 mcg/ml: 
Estimated optimum loading dose = 478 milligrams 
Estimated optimum maintenance dose = 478 milligrams 
Estimated optimum dose interval = 10 hours and 45 minutes 
Though this is the only combination which will achieve the desired serum 
maximum and minimum level, different — and perhaps more convenient — 
combinations of dose and interval can be selected to give a similar 
area-under-the curve (AUC). 
Would you like another dose-interval combination (Y or N) ? Y 
Enter desired interval between maintenance doses 




[h ou r s] 
[h ou rs:minu tes] 
[hou rs ] 
Desired interval [hr:min]? 12 
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nter snallest practical division in which your preparation of 
spectinomycin can be dispensed — often corresponds to 1/2 tablet 
Examp le: 
2.5 [mi lligrams ] 
mallest division (in milligrams)? 250 
* 
djusted maintenance dose * 500 milligrams 
nter date for 1st dose (press <RETURN> for today): F 
nter snellest practical division in which your preparation of 
spectinomycin can be dispensed — often corresponds to 1/2 tablet 
Examp le: 
2.5 [m i 1 li g rams ] 
mallest division (in milligrams)? 250 
djusted maintenance dose = 500 milligrams 
nter date for 1st dose (press <RETURN> for today): FEB 28 , 198 2 
titer time for 1st spectinomycin dose 
nter time 





ime? 8 AM 
ESTIMATED BLOOD LEVELS FOR SPECTINOMYCIN 
DOSE DOSE 
ATE TIME COUNT MILLIGRAMS 
eb 28 8:00 AM 1st 500 
eb 28 8:00 PM 2nd 500 
ar 1 8 :00 AM 3rd 500 
ar 1 8:00 PM 4 th 500 
ar 2 8:00 AM 5 th 500 
ar 2 8:00 PM 6th 500 
ar 3 8:00 AM 7th 500 
ar 3 8:00 PM 8th 500 
ar 4 8:00 AM 9th 500 
ar 4 8:00 PM 10th 500 
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